Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viruses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    341 result(s) found for: Viruses. Displaying page 2 of 18.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000685-42 Sponsor Protocol Number: 2DR-study Start Date*: 2020-04-30
    Sponsor Name:Ghent University Hospital
    Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.
    Medical condition: human immunodeficiency viruses (HIV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-005015-29 Sponsor Protocol Number: GS101-P2-CG Start Date*: 2005-08-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal ne...
    Medical condition: Patients suffering from keratitis or keratouveitits of infectious origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004252-60 Sponsor Protocol Number: RTQ-15-TKU Start Date*: 2014-12-16
    Sponsor Name:Vaccine Research Center, University of Tampere
    Full Title: Shedding and immune response of rotavirus vaccine (RotaTeq)
    Medical condition: Test subjects are healthy.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003701-26 Sponsor Protocol Number: D2560C00013 Start Date*: 2018-10-11
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005860-31 Sponsor Protocol Number: 111870 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age
    Medical condition: Diseases caused by measles, mumps, rubella and varicella viruses
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000722-26 Sponsor Protocol Number: AVM-003-HC Start Date*: 2021-01-11
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans...
    Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10059348 Viral hemorrhagic cystitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002785-13 Sponsor Protocol Number: V130_10 Start Date*: 2020-12-04
    Sponsor Name:Seqirus Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United State...
    Medical condition: Prophylaxis of Influenza Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003931-40 Sponsor Protocol Number: BRD/05/95 Start Date*: 2006-04-20
    Sponsor Name:University College London
    Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma
    Medical condition: Angioimmunoblastic T-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001918-33 Sponsor Protocol Number: 107507 Start Date*: 2006-06-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influspit SSW®) 2006/2007 in people aged 18 years or above
    Medical condition: immunization against influenza of healthy adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006065-14 Sponsor Protocol Number: 105908 Start Date*: 2006-04-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
    Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003592-35 Sponsor Protocol Number: LAIVImmuno Start Date*: 2014-04-07
    Sponsor Name:Public Health England
    Full Title: A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, o...
    Medical condition: Protection against influenza in healthy children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    14.1 10042613 - Surgical and medical procedures 10039244 Routine vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10016794 Flu vaccination LLT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001332-22 Sponsor Protocol Number: RG_12-201 Start Date*: 2013-06-20
    Sponsor Name:University of Birmingham
    Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer
    Medical condition: Exposure to Varicella by children who have cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10046980 Varicella PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001593-26 Sponsor Protocol Number: H 1005 6002 - 05/07 Start Date*: 2005-07-27
    Sponsor Name:HERMAL Kurt Herrmann GmbH & Co OHG
    Full Title: Topical treatment of verrucae vulgares with Verrumal® in organtransplant recipients (OTR) – prospective, double-blind, placebo-controlled randomised trial
    Medical condition: Verrucae vulgares or common warts are benign epithelial tumors of the skin caused by infection with human papilloma viruses (HPV). Due to immunosuppression organ transplant recipients are at high r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003378-28 Sponsor Protocol Number: 2013071339 Start Date*: 2014-04-09
    Sponsor Name:Department of Medicine, Køge University Hospital [...]
    1. Department of Medicine, Køge University Hospital
    2. Department of Medicine, Køge University Hospital
    Full Title: THE ROLE OF PHAGES IN MICROBIAL GUT ECOLOGY A STUDY OF INTERACTIONS BETWEEN ANTIBIOTICS AND THE GUT MICROBIOTA IN HEALTHY VOLUNTEERS A PARALLEL, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY
    Medical condition: Resistance to anitbiotics
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10004052 Bacterial resistance LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001608-37 Sponsor Protocol Number: 115555MMRV-063 Start Date*: 2011-12-16
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA
    Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell...
    Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000620-26 Sponsor Protocol Number: MK-3682B-034 Start Date*: 2016-11-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic H...
    Medical condition: Chronic Hepatitis C Infected Patient
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003936-25 Sponsor Protocol Number: RLX0120 Start Date*: 2020-10-31
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie...
    Medical condition: Adult paucisymptomatic COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004847-61 Sponsor Protocol Number: 008717QM Start Date*: 2013-01-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:30:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA